Staging preview: health content pending qualified review
D2C Peptides

Research goal

Peptides and muscle growth

No peptide on this page has trial evidence that it builds both muscle and strength in healthy people.351 Even growth hormone itself added about 2 kg of lean mass in trials of fit young adults, partly as body water, without clear strength gains.118 The growth hormone releasers were mostly tested for hormone levels, not muscle.2 This page maps what published sources report on each compound and makes no promise.

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

Growth hormone: the reference point

HGH

The growth hormone releasers on this page act by raising the body's own growth hormone (GH), so GH itself is the benchmark.2 In a systematic review of 27 study groups of fit young adults (303 given GH), lean body mass rose 2.1 kg.1 Strength and exercise capacity did not appear to improve, and swelling and fatigue were more common.1 In a randomized trial of 96 recreational athletes, 8 weeks of GH added lean mass mostly as body water.18 Sprint capacity rose 3.9%, a gain gone 6 weeks after stopping, while strength, power and endurance did not change.18 In older men, strength did not rise significantly, apart from a borderline gain with GH plus testosterone.19 Profile: What is HGH?. Research vial: HGH for sale.

Growth hormone releasers

Sermorelin

In 11 healthy older men, nightly sermorelin injections for 6 weeks improved 2 of 6 strength tests and one endurance test.20 DEXA scans showed no change in muscle or fat.2021 In 19 adults aged 55 to 71, a related analog (not sermorelin itself) raised lean body mass over 16 weeks in the men only.22 A 2026 review calls the benefits in healthy people uncertain because the human evidence is limited and largely indirect.23 The sermorelin and muscle page covers these studies in full. Profile: What is Sermorelin?. Research vial: Sermorelin for sale.

Tesamorelin

Tesamorelin is FDA approved only to reduce excess abdominal fat in adults with HIV and lipodystrophy.24 In its two main trials, lean body mass rose 1.3 kg and 1.2 kg from baseline over 26 weeks.10 It fell 1.8 kg and 1.7 kg in patients then switched to placebo.1011 A secondary analysis found larger, denser skeletal muscle in patients whose deep belly fat fell on treatment.25 Profile: What is Tesamorelin?. Research vial: Tesamorelin for sale.

CJC-1295

No human study of any form of CJC-1295 has measured muscle: FDA notes that its three human studies, all in healthy adults, did not measure body composition.26 In one, a single injection raised average GH 2- to 10-fold for 6 days or more, and IGF-1 1.5- to 3-fold for 9 to 11 days.27 The only lean mass data come from GHRH-knockout mice, where lean mass was normal after treatment.28 The form without DAC has no controlled human studies at all.2 Read What is CJC-1295 with DAC? and What is CJC-1295 No DAC?, or see CJC-1295 with DAC for sale and CJC-1295 No DAC for sale.

Ipamorelin

Ipamorelin's two published clinical trials studied its blood levels and gut recovery after surgery, not muscle.292 In female rats given a steroid for 3 months, adding ipamorelin preserved calf muscle strength, and in prednisolone-treated rats it reduced nitrogen wasting.3031 Paired with CJC-1295, it improved muscle force in mice with steroid-induced muscle loss.3 Read What is Ipamorelin? and What is CJC-1295 + Ipamorelin?, or see Ipamorelin for sale and CJC-1295 + Ipamorelin for sale.

GHRP-2

Human studies of GHRP-2 measured hormones and appetite, not muscle size or strength.232 In 17 older adults, a 30-day infusion kept GH and IGF-1 raised, with no muscle outcome reported in the abstract.32 In steroid-treated rats and in muscle cells, it lowered genes that drive muscle breakdown.33 Profile: What is GHRP-2?. Research vial: GHRP-2 for sale.

GHRP-6

Human studies of GHRP-6 measured short-term hormone changes, such as IGF-1 rising from 252 to 312 micrograms per liter during a 34-hour infusion in 9 men.34 A 2026 review notes a consistent rise in appetite and says direct evidence for body composition changes remains limited.35 Profile: What is GHRP-6?. Research vial: GHRP-6 for sale.

IGF-1 LR3

IGF-1 LR3 has never been tested in a registered human trial.4 In growing female rats it raised weight gain and nitrogen retention, while muscle protein synthesis rose only slightly.56 Trials of natural IGF-1 in 16 older women and 56 athletes found no lean mass gain.78 Profile: What is IGF-1?. Research vial: IGF-1 for sale.

MGF

In human muscle cell cultures, the MGF E peptide extended the growth of muscle stem cells from younger donors and increased their fusion.36 Scientists at two drug companies, however, found no effect on human or mouse muscle cells, and a related rodent E-peptide made mouse muscles bigger but weaker.3738 No human study has tested MGF for muscle.39 Profile: What is MGF?. Research vial: MGF for sale.

AOD-9604 and HGH Fragment 176-191

Both are fragments from the end of the growth hormone molecule.40 In sponsor trials of 893 mostly obese adults, AOD-9604 did not raise IGF-1,40 and in cell tests it did not bind the growth hormone receptor.41 No study measuring muscle with either fragment was found.42 Read What is AOD-9604? and What is HGH Fragment 176-191?, or see AOD-9604 for sale and HGH Fragment 176-191 for sale.

Healing peptides listed under muscle growth

BPC-157

BPC-157 has not been shown to build muscle.43 Its rat muscle study tested healing of a cut quadriceps over 72 days, not growth.44 The three human studies, in 30 people in total, covered knee pain, bladder pain and IV safety, and none measured muscle size or strength.43 A trial of BPC-157 for acute hamstring strain was registered and recruiting in 2026, with no results yet.45 Profile: What is BPC-157?. Research vial: BPC-157 for sale.

TB-500

Muscle growth is a marketing claim for TB-500, not a study finding.46 FDA lists "increasing muscle growth and muscle tone" among the uses it is marketed for online, and found no article in which TB-500 was given to people.46 Profile: What is TB-500?. Research vial: TB-500 for sale.

Wolverine Stack

This blend pairs BPC-157 with TB-500, and its research concerns healing of injured tissue, mostly in animals.47 In a 2026 rat tendon study, the two together gave no added benefit over either alone.48 The healing and recovery page covers that research. Profile: What is Wolverine Stack (BPC-157 + TB-500)?. Research vial: Wolverine Stack (BPC-157 + TB-500) for sale.

GHK-Cu

In mice exposed to cigarette smoke, GHK-Cu treatment reduced muscle loss and improved grip strength.49 A 2026 review of injectable peptides found no clinical data supporting GHK-Cu for musculoskeletal conditions.50 Profile: What is GHK-Cu?. Research vial: GHK-Cu for sale.

Mitochondrial and metabolic compounds

MOTS-c

In mice, MOTS-c injections improved treadmill performance and protected against muscle wasting.5152 In people, exercise raised the body's own MOTS-c in muscle and blood in one small study,53 but another found only a trend in blood and no change in muscle.54 FDA found no clinical studies or human exposure data for MOTS-c given as a drug.55 Profile: What is MOTS-c?. Research vial: MOTS-c for sale.

SS-31

As elamipretide (FORZINITY), SS-31 has accelerated FDA approval to improve muscle strength in patients with Barth syndrome, a rare genetic disease, who weigh at least 30 kg.5658 Strength gains were not seen in the randomized trial, only in its open-label extension, and continued approval may depend on a confirmatory trial.57 In 218 adults with primary mitochondrial myopathy, it did not improve walking distance or fatigue.59 Profile: What is SS-31?. Research vial: SS-31 for sale.

NAD+

In 80 healthy middle-aged adults, oral NMN, an NAD+ precursor, increased six-minute walk distance more than placebo over 60 days, in an industry-funded trial.6061 In human trials of another precursor, nicotinamide riboside, muscle mitochondrial function did not change.62 Profile: What is NAD+?. Research vial: NAD+ for sale.

Semaglutide, tirzepatide and retatrutide

These GLP-1 drugs do not build muscle.6364 The Wegovy and Zepbound labels state that semaglutide and tirzepatide lower body weight with greater fat loss than lean mass loss, so some lean mass is lost too.6364 In a phase 2 substudy of retatrutide in adults with type 2 diabetes, fat mass fell by up to 26.1%.65 The share of weight lost as lean mass was similar to other obesity treatments.65 Read What is Semaglutide?, What is Tirzepatide? and What is Retatrutide?.

Compounds with no muscle data

  • DSIP. In 8 healthy women it did not change growth hormone or prolactin secretion.66 Read What is DSIP?.
  • HCG. No study reviewed for this site shows that hCG builds muscle, and WADA bans it in male athletes at all times.1567 Read What is HCG?.
  • Thymosin Alpha-1. FDA found a lack of evidence for the uses it evaluated, and no study reviewed for this site measured muscle or strength.68 Read What is Thymosin Alpha-1?.
  • KPV. FDA notes KPV is promoted in compounded combinations for muscle and joint repair, but it found no human data for KPV by any route.69 Read What is KPV?.
  • Glow and KLOW blends. No published human study links either blend or its ingredients to muscle growth. Human BPC-157 studies covered knee pain, bladder pain and IV safety, FDA found no human TB-500 or KPV studies, and no clinical data support GHK-Cu for musculoskeletal use.43466950 Read What is Glow Peptide Stack? and What is KLOW Peptide Blend?.

Anti-doping status

The 2026 WADA Prohibited List bans most of the compounds on this page at all times, in and out of competition.14 Its peptide hormone class covers GHRH analogs (including CJC-1295, sermorelin and tesamorelin), secretagogues such as ipamorelin, and GHRP-1 to GHRP-6.14 It also covers GH fragments including AOD-9604 and hGH 176-191, IGF-1 analogues, mechano growth factors and TB-500, and it names BPC-157 among unapproved substances.14 GLP-1 drugs are not on the list.17

How to read this research

A muscle claim needs people, not just hormone levels or animals, and it needs more strength as well as more lean mass. GH shows why both matter: lean mass rose about 2 kg in fit young adults, partly as water, while strength did not clearly improve.118 Hormone levels are not outcomes either. CJC-1295 and the GHRPs raise GH and IGF-1, but no controlled trial has followed that through to muscle.2 Animal models need care too: steroid-treated rats and smoke-exposed mice test protection against wasting, and a cut-muscle study tests healing.304944 A 2026 review of peptide supplements in sports medicine found that 67% of publications used animal models, and that human studies mostly lacked robust controls.70 The profile pages linked above give each compound's side effects and regulatory status, and the safety basics guide covers how to weigh compounds that are not approved.

Compound by compound

  • Sermorelin and muscle growth

    What published sources report on Sermorelin and muscle growth, with links to the Sermorelin profile and the muscle growth hub.

Other research goals

Frequently asked questions

Can CJC-1295 and Ipamorelin help with muscle growth?

That has not been shown in people. A 2026 review calls controlled evidence for the pair limited,2 and the human studies of each peptide measured growth hormone, IGF-1 or gut recovery after surgery, not muscle.26292 The combination improved muscle force only in mice with steroid-induced muscle loss.3 Even growth hormone itself, which these peptides release, added about 2 kg of lean mass in fit young adults without clear strength gains.1

Does IGF-1 LR3 increase muscle?

No registered human trial has tested it: a ClinicalTrials.gov search for IGF-1 LR3 and its other names returns no studies.4 Over 14 days in growing female rats it increased weight gain and nitrogen retention, while muscle protein synthesis rose only slightly.56 Trials of recombinant human IGF-1, a different form, found no lean mass gain in 16 older women over a year or in 56 athletes over 28 days.78

What are the results of using tesamorelin in bodybuilding?

None of the 24 registered tesamorelin studies tests muscle gain in bodybuilders or healthy athletes.9 Its results come from adults with HIV, where lean body mass rose 1.2 to 1.3 kg from baseline over 26 weeks and fell again in those switched to placebo.1011 A 2026 review notes it has no approval for physique or performance uses,12 and the WADA list bans it in and out of competition.13

Are muscle growth peptides banned in sport?

Most are.14 WADA's 2026 list bans growth hormone releasers, growth hormone fragments and IGF-1 analogues at all times.14 Chorionic gonadotrophin (hCG) is banned in male athletes as a testosterone-stimulating peptide.15 USADA reports that the 2027 list also names peptides in general as prohibited.16 GLP-1 drugs such as semaglutide and tirzepatide are not on the list, and WADA kept that status for 2027.17

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. Systematic review: the effects of growth hormone on athletic performance (Liu et al.). Annals of Internal Medicine (PubMed abstract), 2008.
  2. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Dominikowski et al., Front Endocrinol 17:1822475). Frontiers in Endocrinology (PMC full text, PMC13322892), 2026.
  3. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (Mayfield CK et al.). American Journal of Sports Medicine, 2026.
  4. ClinicalTrials.gov API query: all fields for 'IGF-1 LR3', 'Long R3 IGF-I', 'LR3 IGF-1', 'Long R3 IGF-1' or 'LongR3' (run October 24, 2026). ClinicalTrials.gov, U.S. National Library of Medicine, 2026.
  5. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats (Tomas et al.), abstract: design and effects. Journal of Endocrinology (PubMed PMID 8371075), 1993.
  6. Same source as 5: Tomas et al. 1993 (J Endocrinol), abstract: muscle protein turnover.
  7. Friedlander et al. 2001, abstract: conclusion. Journal of Clinical Endocrinology and Metabolism (PubMed PMID 11297574), 2001.
  8. Guha et al. 2015, abstract: results. Journal of Clinical Endocrinology and Metabolism (PubMed PMID 26046967), 2015.
  9. ClinicalTrials.gov API search: studies with tesamorelin as an intervention (count). ClinicalTrials.gov, U.S. National Library of Medicine, 2026.
  10. EGRIFTA WR prescribing information: 14 Clinical Studies (lean body mass). U.S. Food and Drug Administration (Drugs@FDA label, BLA 022505), 2025.
  11. Same source as 10: Extension Phase (lean body mass after switching to placebo).
  12. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Dominikowski A et al.). Front Endocrinol (Lausanne) (PubMed abstract via NCBI E-utilities), 2026.
  13. Tractatenblad 2026, 25: Anti-doping Convention, amendment to the appendix (The 2026 Prohibited List, World Anti-Doping Code), S2.2.4. Ministry of Foreign Affairs of the Netherlands (official Treaty Series publication of the WADA 2026 Prohibited List text), 2026.
  14. World Anti-Doping Code International Standard: Prohibited List 2026 (in effect 1 January 2026). World Anti-Doping Agency (WADA), 2025.
  15. The 2026 Prohibited List, World Anti-Doping Code, as published in Tractatenblad 2026 nr. 25: S2.2.1. World Anti-Doping Agency list, published by the Kingdom of the Netherlands (Tractatenblad), 2026.
  16. Athlete Advisory: What's New on the 2027 WADA Prohibited List? U.S. Anti-Doping Agency (USADA), 2026.
  17. WADA publishes 2027 Prohibited List. World Anti-Doping Agency, 2026.
  18. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial (Meinhardt et al.). Annals of Internal Medicine (PubMed abstract), 2010.
  19. Blackman MR et al. 2002 (PMID 12425705): strength in men. JAMA, via PubMed (NCBI E-utilities), 2002.
  20. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men (Vittone et al.), strength. Metabolism (PubMed abstract PMID 9005976, via NCBI E-utilities), 1997.
  21. Same source as 20: body composition and safety.
  22. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women (Khorram et al.), body composition and skin. J Clin Endocrinol Metab (PubMed abstract PMID 9141536, via NCBI E-utilities), 1997.
  23. Same source as 2: The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis (Dominikowski et al.), evidence for benefits.
  24. EGRIFTA WR (tesamorelin) for injection, prescribing information (revised 3/2025). DailyMed, U.S. National Library of Medicine (label by Theratechnologies), 2025.
  25. The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV (Adrian S et al.): conclusion. J Frailty Aging (PubMed abstract via NCBI E-utilities), 2019.
  26. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 50, effectiveness). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  27. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (Teichman et al.). Journal of Clinical Endocrinology and Metabolism (PubMed abstract), 2006.
  28. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse (Alba M et al.), PubMed PMID 16822960. American Journal of Physiology, Endocrinology and Metabolism (abstract via NCBI PubMed E-utilities), 2006.
  29. PubMed search: ipamorelin AND clinical trial[pt] (NCBI E-utilities). National Library of Medicine (NIH), PubMed.
  30. Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats (PubMed abstract, PMID 11735244). Growth Hormone & IGF Research, 2001.
  31. Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats (PubMed abstract, PMID 19231263). Growth Hormone & IGF Research, 2009.
  32. Sustained elevation of pulsatile GH secretion and IGF-I, IGFBP-3, and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women (Bowers CY et al.). Journal of Clinical Endocrinology and Metabolism (PubMed record via NCBI E-utilities), 2004.
  33. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1 (Yamamoto D et al.). Life Sciences (PubMed record via NCBI E-utilities), 2008.
  34. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men (Jaffe CA et al.; PMID 7903313). Journal of Clinical Endocrinology and Metabolism (abstract via NCBI PubMed E-utilities), 1993.
  35. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Dominikowski A et al.; full text). Frontiers in Endocrinology, 2026.
  36. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages (Kandalla PK, et al.). Mechanisms of Ageing and Development, 2011.
  37. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells (Fornaro M, et al.). American Journal of Physiology: Endocrinology and Metabolism, 2014.
  38. Viral expression of insulin-like growth factor I E-peptides increases skeletal muscle mass but at the expense of strength (Brisson BK, et al.). American Journal of Physiology: Endocrinology and Metabolism, 2014.
  39. Same source as 35: bridging the gap between clinical evidence and patient self-administration (Dominikowski A, et al.), full text.
  40. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (Stier H, Vos E, Kenley D); authors tied to the developer, Metabolic Pharmaceuticals. Journal of Endocrinology and Metabolism (Elmer Press), 2013.
  41. Heffernan 2001 (Int J Obes), PubMed abstract: receptor and proliferation tests. International Journal of Obesity 25(10):1442-9, 2001.
  42. Same source as 40: Stier 2013: abstract, IGF-1 result.
  43. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety (Poolton JT, Minett J, Kazmi A; PMID 42885452). Acta Orthopaedica Belgica (PubMed abstract via NCBI E-utilities), 2026.
  44. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157 (Staresinic M, et al.; PMID 16609979). Journal of Orthopaedic Research (PubMed abstract via NCBI E-utilities), 2006.
  45. ClinicalTrials.gov API v2: NCT07437547 title and status. ClinicalTrials.gov, U.S. National Library of Medicine, 2026.
  46. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: TB-500-Related Bulk Drug Substances (TB-500 (Free Base) and TB-500 acetate). U.S. Food and Drug Administration, 2026.
  47. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi N, et al.; PMID 40756949). HSS Journal, 2025.
  48. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (Biçer O, Adanir O, et al.; PMID 42542926). Joint Diseases and Related Surgery, 2026.
  49. Deng M, et al. Glycyl-l-histidyl-l-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway (PubMed 36905132), mouse results. Journal of Cachexia, Sarcopenia and Muscle, 2023.
  50. Same source as 3: Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (PubMed 41476424), results.
  51. FDA Briefing Document: Evaluation of MOTS-c-Related Bulk Drug Substances, PCAC July 23-24, 2026 (summary of Reynolds et al. 2021). U.S. Food and Drug Administration, 2026.
  52. MOTS-c modulates skeletal muscle function by directly binding and activating CK2 (Kumagai et al.). iScience, 2024.
  53. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds et al.). Nature Communications, 2021.
  54. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans (von Walden et al.). Journal of Applied Physiology, 2021.
  55. Same source as 51: Evaluation of MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate), PCAC meeting July 23-24, 2026, memo dated 5/11/2026 (human safety section).
  56. FORZINITY (elamipretide) injection prescribing information: Indications and Usage. DailyMed, U.S. National Library of Medicine (label by Stealth BioTherapeutics Inc., revised 9/2025), 2025.
  57. Same source as 56: FORZINITY prescribing information: Clinical Studies (knee extensor strength).
  58. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome (confirmatory trial). U.S. Food and Drug Administration, 2025.
  59. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial (enrollment and outcome). Neurology (PubMed abstract, PMID 37268435), 2023.
  60. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults (Yi et al.): outcomes. GeroScience (via PMC), 2023.
  61. Same source as 60: safety and funding.
  62. What is really known about the effects of nicotinamide riboside supplementation in humans (Damgaard and Treebak). Science Advances (via PMC), 2023.
  63. WEGOVY (semaglutide) prescribing information, sections 12.1 and 12.2 Pharmacodynamics. DailyMed, U.S. National Library of Medicine (Novo Nordisk label, revised 6/2026), 2026.
  64. ZEPBOUND Prescribing Information, revised 08/2026: Pharmacodynamics (body composition, calorie intake). U.S. Food and Drug Administration (label for Eli Lilly and Company), 2026.
  65. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology (PubMed record, National Library of Medicine), 2025.
  66. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women (Giusti et al.). Psychoneuroendocrinology (abstract via PubMed, NLM), 1993.
  67. Same source as 15: S2 class status.
  68. Thymosin Alpha-1 (Ta1) Related Bulk Drug Substances (FDA presentation slides, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024). U.S. Food and Drug Administration, 2024.
  69. FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List, FDA briefing document for the July 23-24, 2026 PCAC meeting (memo dated 5/12/2026). U.S. Food and Drug Administration, 2026.
  70. Peptide Supplements and Their Therapeutic Applications in Sports Medicine (Tewari K et al.). American Journal of Sports Medicine, 2026.